PT2280721T - Imunoterapia à base de indoleamina 2,3-dioxigenase - Google Patents

Imunoterapia à base de indoleamina 2,3-dioxigenase

Info

Publication number
PT2280721T
PT2280721T PT97535561T PT09753556T PT2280721T PT 2280721 T PT2280721 T PT 2280721T PT 97535561 T PT97535561 T PT 97535561T PT 09753556 T PT09753556 T PT 09753556T PT 2280721 T PT2280721 T PT 2280721T
Authority
PT
Portugal
Prior art keywords
indoleamine
dioxygenase
therapy based
immune therapy
immune
Prior art date
Application number
PT97535561T
Other languages
English (en)
Portuguese (pt)
Inventor
Hald Andersen Mads
Thor Straten Per
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of PT2280721T publication Critical patent/PT2280721T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT97535561T 2008-04-17 2009-04-17 Imunoterapia à base de indoleamina 2,3-dioxigenase PT2280721T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17

Publications (1)

Publication Number Publication Date
PT2280721T true PT2280721T (pt) 2018-02-16

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97535561T PT2280721T (pt) 2008-04-17 2009-04-17 Imunoterapia à base de indoleamina 2,3-dioxigenase
PT171946197T PT3320912T (pt) 2008-04-17 2009-04-17 Imunoterapia à base de indoleamina 2,3-dioxigenase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT171946197T PT3320912T (pt) 2008-04-17 2009-04-17 Imunoterapia à base de indoleamina 2,3-dioxigenase

Country Status (20)

Country Link
US (7) US9433666B2 (OSRAM)
EP (3) EP3915570A1 (OSRAM)
JP (2) JP2011520783A (OSRAM)
CN (2) CN104056261B (OSRAM)
AU (1) AU2009253539B2 (OSRAM)
CA (1) CA2721150C (OSRAM)
CY (2) CY1120352T1 (OSRAM)
DK (2) DK2280721T3 (OSRAM)
ES (2) ES2870596T3 (OSRAM)
HR (2) HRP20180282T1 (OSRAM)
HU (2) HUE037973T2 (OSRAM)
IL (1) IL208781A (OSRAM)
LT (2) LT3320912T (OSRAM)
NO (1) NO2280721T3 (OSRAM)
NZ (1) NZ588757A (OSRAM)
PL (2) PL2280721T3 (OSRAM)
PT (2) PT2280721T (OSRAM)
SI (2) SI2280721T1 (OSRAM)
WO (1) WO2009143843A1 (OSRAM)
ZA (1) ZA201008056B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2280721T1 (en) * 2008-04-17 2018-02-28 Io Biotech Aps C/O Cobis Indoleamine 2, 3-dioxygenase based immunotherapy
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2947650C (en) * 2014-05-29 2021-04-27 Spring Bioscience Corporation Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
US10736950B2 (en) 2014-09-17 2020-08-11 Herlev Hospital Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
EP3313431B1 (en) 2015-06-29 2023-11-15 OSE Immunotherapeutics Method for inducing early t memory response with short peptides anti-tumor vaccine
EP3349785A1 (en) 2015-09-16 2018-07-25 Herlev Hospital Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
WO2017149150A1 (en) 2016-03-04 2017-09-08 Io Biotech Aps Combination therapy against cancer
US20190328857A1 (en) 2016-06-10 2019-10-31 Io Biotech Aps Calr and jak2 vaccine compositions
WO2018067660A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
DK3526347T3 (da) * 2016-10-14 2021-02-15 Univ Zuerich Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer
KR20250067948A (ko) * 2017-01-20 2025-05-15 아타라 바이오테라퓨틱스 인크. 자가 t 세포를 사용하여 다발성 경화증을 치료하는 방법
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
MX2020005454A (es) 2017-11-27 2020-08-27 Ose Immunotherapeutics Tratamiento de cancer mejorado.
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
AU2020371562A1 (en) * 2019-10-23 2022-06-09 The Council Of The Queensland Institute Of Medical Research Adoptive immunotherapy
US20230173056A1 (en) * 2020-07-02 2023-06-08 The Regents Of The University Of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
EP4651896A1 (en) * 2023-01-17 2025-11-26 Regeneron Pharmaceuticals, Inc. Inositol polyphosphate multikinase (ipmk) therapeutic agents or indoleamine 2,3-dioxygenase 2 (ido2) agonists for use in treating b27-negative uveitis
WO2024178160A2 (en) * 2023-02-21 2024-08-29 Salvitus, Inc. Recombinant phage, probiotic vaccines and therapeutics, related compositions and methods of use
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1997000966A1 (en) * 1995-06-20 1997-01-09 Merck & Co., Inc. Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
JP3676380B2 (ja) 1996-06-12 2005-07-27 シャンハイ・シーピー・グオジャン・ファーマシューティカル・カンパニー・リミテッド 細胞性ワクチンおよび免疫療法薬ならびにそれらの製造方法
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
WO2000066764A1 (en) 1999-05-03 2000-11-09 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
WO2003087347A1 (en) 2002-04-12 2003-10-23 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US7763251B2 (en) 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060205934A1 (en) 2002-12-05 2006-09-14 Macina Roberto A Compositions, splice variants and methods relating to breast specific genes and proteins
WO2004054615A1 (en) 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
CA2520586C (en) 2003-03-27 2011-06-14 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20050186289A1 (en) 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
WO2006005185A1 (en) * 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (ido) inhibitors
US20060110371A1 (en) 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
ES2523172T3 (es) 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
BR122020016659B8 (pt) 2005-05-10 2021-07-27 Incyte Holdings Corp moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
DK1926813T4 (da) * 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2008143668A2 (en) * 2006-05-18 2008-11-27 Lankenau Institute For Medical Research Indoleamine-2, 3-dioxygenase-2
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
SI2280721T1 (en) 2008-04-17 2018-02-28 Io Biotech Aps C/O Cobis Indoleamine 2, 3-dioxygenase based immunotherapy

Also Published As

Publication number Publication date
HUE055338T2 (hu) 2021-11-29
PT3320912T (pt) 2021-05-24
DK2280721T3 (da) 2018-01-29
JP2015129182A (ja) 2015-07-16
US20110318372A1 (en) 2011-12-29
US20220249641A1 (en) 2022-08-11
US10258678B2 (en) 2019-04-16
DK3320912T3 (da) 2021-05-31
EP2280721B1 (en) 2017-11-15
ES2870596T3 (es) 2021-10-27
CY1124279T1 (el) 2022-07-22
HRP20180282T1 (hr) 2018-03-23
CY1120352T1 (el) 2019-07-10
US20170049868A1 (en) 2017-02-23
US20220202922A1 (en) 2022-06-30
CN102088994A (zh) 2011-06-08
IL208781A0 (en) 2010-12-30
US20230233657A1 (en) 2023-07-27
CN102088994B (zh) 2014-06-25
PL3320912T3 (pl) 2021-10-25
WO2009143843A1 (en) 2009-12-03
NZ588757A (en) 2012-05-25
HRP20210766T1 (hr) 2021-07-23
HUE037973T2 (hu) 2018-09-28
EP3320912A1 (en) 2018-05-16
NO2280721T3 (OSRAM) 2018-04-14
US12233103B2 (en) 2025-02-25
US20250319159A1 (en) 2025-10-16
SI3320912T1 (sl) 2021-08-31
PL2280721T3 (pl) 2018-04-30
US11648302B2 (en) 2023-05-16
US9433666B2 (en) 2016-09-06
EP3915570A1 (en) 2021-12-01
EP3320912B1 (en) 2021-03-31
ES2657963T3 (es) 2018-03-07
AU2009253539B2 (en) 2014-03-20
ZA201008056B (en) 2011-07-27
US11324813B2 (en) 2022-05-10
CA2721150C (en) 2017-09-26
AU2009253539A1 (en) 2009-12-03
SI2280721T1 (en) 2018-02-28
US20190201512A1 (en) 2019-07-04
JP2011520783A (ja) 2011-07-21
CN104056261A (zh) 2014-09-24
EP2280721A1 (en) 2011-02-09
CA2721150A1 (en) 2009-12-03
CN104056261B (zh) 2017-01-11
JP6016966B2 (ja) 2016-10-26
LT3320912T (lt) 2021-07-12
LT2280721T (lt) 2018-02-12
IL208781A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
PT2280721T (pt) Imunoterapia à base de indoleamina 2,3-dioxigenase
SMT201400179B (it) 1,2,5-Ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
LTPA2018006I1 (lt) Pakeistųjų oksazolidinonų kombinuota terapija
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DK2175851T3 (da) Biofilmbehandling
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
PL2660248T3 (pl) Nowa immunoterapia przeciwko nowotworom mózgu
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
JP2011175111A5 (OSRAM)
BRPI0915099A2 (pt) Antioxidante altamente eficaz à base de trealulose.
EP2887943A4 (en) Novel 4,6-DISUBSTITUTED AMINOPYRIMIDIN DERIVATIVES
EP2185273A4 (en) INDUCTIVE DESALINATION IN THE RADIAL CURRENT
DK2173831T3 (da) Brøndbehandling
EP2692825A4 (en) PHOSPHORUS ON OXINITRIDE BASE
FR2973218B1 (fr) Plaque d'osteosynthese.
EP2730555A4 (en) COMPOSITION WITH 1,4-BUTANEDIOL
BRPI0818598A2 (pt) agentes terapêuticos - 802
IT1394301B1 (it) Calzatura sportiva, particolarmente per uso calcistico e simili.
BRPI0912193A2 (pt) compostos terapêuticos.
DK2042015T3 (da) Centrifugalspreder
ITRM20080108A1 (it) Tapis roulant perfezionato.
JP2011219902A5 (OSRAM)
IT1390810B1 (it) Calzatura regolabile
ES1066103Y (es) Asador de mesa
DE112008000061A5 (de) Riemenscheibe